These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

428 related items for PubMed ID: 30354362

  • 1. Effect of Everolimus Initiation and Calcineurin Inhibitor Elimination on Cardiac Allograft Vasculopathy in De Novo Heart Transplant Recipients.
    Arora S, Andreassen AK, Karason K, Gustafsson F, Eiskjær H, Bøtker HE, Rådegran G, Gude E, Ioanes D, Solbu D, Dellgren G, Ueland T, Aukrust P, Gullestad L, SCHEDULE (Scandinavian Heart Transplant Everolimus De Novo Study With Early Calcineurin Inhibitors Avoidance) Investigators.
    Circ Heart Fail; 2018 Sep; 11(9):e004050. PubMed ID: 30354362
    [Abstract] [Full Text] [Related]

  • 2. Everolimus Initiation With Early Calcineurin Inhibitor Withdrawal in De Novo Heart Transplant Recipients: Long-term Follow-up From the Randomized SCHEDULE Study.
    Gustafsson F, Andreassen AK, Andersson B, Eiskjær H, Rådegran G, Gude E, Jansson K, Solbu D, Karason K, Arora S, Dellgren G, Gullestad L, SCHEDULE (Scandinavian heart transplant everolimus de novo study with early calcineurin inhibitors avoidance) Investigators*.
    Transplantation; 2020 Jan; 104(1):154-164. PubMed ID: 30893292
    [Abstract] [Full Text] [Related]

  • 3. The Effect of Everolimus Initiation and Calcineurin Inhibitor Elimination on Cardiac Allograft Vasculopathy in De Novo Recipients: One-Year Results of a Scandinavian Randomized Trial.
    Arora S, Andreassen AK, Andersson B, Gustafsson F, Eiskjaer H, Bøtker HE, Rådegran G, Gude E, Ioanes D, Solbu D, Sigurdardottir V, Dellgren G, Erikstad I, Solberg OG, Ueland T, Aukrust P, Gullestad L, SCHEDULE (SCandinavian HEart transplant everolimus De novo stUdy with earLy calcineurin inhibitors avoidancE) Investigators.
    Am J Transplant; 2015 Jul; 15(7):1967-75. PubMed ID: 25783974
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Everolimus initiation and early calcineurin inhibitor withdrawal in heart transplant recipients: a randomized trial.
    Andreassen AK, Andersson B, Gustafsson F, Eiskjaer H, Radegran G, Gude E, Jansson K, Solbu D, Sigurdardottir V, Arora S, Dellgren G, Gullestad L, SCHEDULE Investigators.
    Am J Transplant; 2014 Aug; 14(8):1828-38. PubMed ID: 25041227
    [Abstract] [Full Text] [Related]

  • 6. Everolimus Initiation With Early Calcineurin Inhibitor Withdrawal in De Novo Heart Transplant Recipients: Three-Year Results From the Randomized SCHEDULE Study.
    Andreassen AK, Andersson B, Gustafsson F, Eiskjaer H, Rådegran G, Gude E, Jansson K, Solbu D, Karason K, Arora S, Dellgren G, Gullestad L, SCHEDULE investigators.
    Am J Transplant; 2016 Apr; 16(4):1238-47. PubMed ID: 26820618
    [Abstract] [Full Text] [Related]

  • 7. The risk of cancer in kidney transplant recipients may be reduced in those maintained on everolimus and reduced cyclosporine.
    Lim WH, Russ GR, Wong G, Pilmore H, Kanellis J, Chadban SJ.
    Kidney Int; 2017 Apr; 91(4):954-963. PubMed ID: 28109543
    [Abstract] [Full Text] [Related]

  • 8. An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients.
    Sommerer C, Suwelack B, Dragun D, Schenker P, Hauser IA, Witzke O, Hugo C, Kamar N, Merville P, Junge M, Thaiss F, Nashan B, Athena Study Group.
    Kidney Int; 2019 Jul; 96(1):231-244. PubMed ID: 31027892
    [Abstract] [Full Text] [Related]

  • 9. Effect of Calcineurin Inhibitor-Free, Everolimus-Based Immunosuppressive Regimen on Albuminuria and Glomerular Filtration Rate After Heart Transplantation.
    Nelson LM, Andreassen AK, Andersson B, Gude E, Eiskjær H, Rådegran G, Dellgren G, Gullestad L, Gustafsson F.
    Transplantation; 2017 Nov; 101(11):2793-2800. PubMed ID: 28230646
    [Abstract] [Full Text] [Related]

  • 10. Cardiac allograft vasculopathy by intravascular ultrasound in heart transplant patients: substudy from the Everolimus versus mycophenolate mofetil randomized, multicenter trial.
    Kobashigawa JA, Pauly DF, Starling RC, Eisen H, Ross H, Wang SS, Cantin B, Hill JA, Lopez P, Dong G, Nicholls SJ, A2310 IVUS Substudy Investigators.
    JACC Heart Fail; 2013 Oct; 1(5):389-99. PubMed ID: 24621971
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Suppressive effects of conversion from mycophenolate mofetil to everolimus for the development of cardiac allograft vasculopathy in maintenance of heart transplant recipients.
    Watanabe T, Seguchi O, Nishimura K, Fujita T, Murata Y, Yanase M, Sato T, Sunami H, Nakajima S, Hisamatsu E, Sato T, Kuroda K, Hieda M, Wada K, Hata H, Ishibashi-Ueda H, Miyamoto Y, Fukushima N, Kobayashi J, Nakatani T.
    Int J Cardiol; 2016 Jan 15; 203():307-14. PubMed ID: 26523360
    [Abstract] [Full Text] [Related]

  • 14. Effect of everolimus initiation and early calcineurin inhibitor withdrawal on myocardial FOXP3+ regulatory T cells in heart transplantation.
    Mirza K, Gustafsson F, Gullestad L, Arora S, Andersen C.
    Transpl Immunol; 2016 Sep 15; 38():75-7. PubMed ID: 27260644
    [Abstract] [Full Text] [Related]

  • 15. Optimizing the immunosuppressive regimen in heart transplantation.
    Eisen H, Ross H.
    J Heart Lung Transplant; 2004 May 15; 23(5 Suppl):S207-13. PubMed ID: 15093807
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Inflammatory burden of cardiac allograft coronary atherosclerotic plaque is associated with early recurrent cellular rejection and predicts a higher risk of vasculopathy progression.
    Raichlin E, Bae JH, Kushwaha SS, Lennon RJ, Prasad A, Rihal CS, Lerman A.
    J Am Coll Cardiol; 2009 Apr 14; 53(15):1279-86. PubMed ID: 19358941
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of conversion from cyclosporine to everolimus in living-donor kidney transplant recipients: an analysis from the ZEUS study.
    Lehner F, Budde K, Zeier M, Wüthrich RP, Reinke P, Eisenberger U, Mühlfeld A, Arns W, Stahl R, Heller K, Witzke O, Wolters HH, Suwelack B, Klehr HU, Stangl M, Hauser IA, Nadalin S, Porstner M, May C, Paulus EM, Sommerer C, ZEUS Study Investigators.
    Transpl Int; 2014 Nov 14; 27(11):1192-204. PubMed ID: 25070687
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients.
    Eisen HJ, Tuzcu EM, Dorent R, Kobashigawa J, Mancini D, Valantine-von Kaeppler HA, Starling RC, Sørensen K, Hummel M, Lind JM, Abeywickrama KH, Bernhardt P, RAD B253 Study Group.
    N Engl J Med; 2003 Aug 28; 349(9):847-58. PubMed ID: 12944570
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.